R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
2008; Ferrata Storti Foundation; Volume: 93; Issue: 12 Linguagem: Inglês
10.3324/haematol.13440
ISSN1592-8721
AutoresAlejandro Martı́n, E Conde, Montserrat Arnán, Miguel Canales, Guillermo Debén, Juan‐Manuel Sancho, Rafael Andreu, Antonio Salar, Paula García Sánchez, Lourdes Vázquez, Sara Nistal, M.J. Requena, Eva Donato, Javier Gonzalez, Antonio Léon, Camilo Ruiz, Carlos Grande, Eva González‐Barca, Marı́a Dolores Caballero,
Tópico(s)Lung Cancer Treatments and Mutations
ResumoBackground The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP).Design and Methods We retrospectively analyzed 163 patients with relapsed or refractory diffuse large B-cell lymphoma who received R-ESHAP as salvage therapy with a curative purpose. Patients were divided into two groups according to whether rituximab had been administered (n=94, "R+" group) or not (n=69, "R-" group) prior to R-ESHAP.Results Response rates were significantly higher in the R- group in the univariate but not in the multivariate analysis. In the analysis restricted to the R+ group, we observed very low complete remission and overall response rates in patients with primary refractory disease (8% and 33%, respectively), as compared to those in patients who were in first partial remission (41% and 86%) or who had relapsed disease (50% and 75%) (p
Referência(s)